Pharmacists May Help Patients Prevent And Detect Heart Disease

In honor of Cholesterol Education Month, The American Pharmacists Association (APhA) would like to highlight the increasing role of the pharmacist in communities nationwide. In many areas, pharmacists are able to offer cholesterol and blood pressure screenings, as well as other detection and prevention services to help a patient manage their healthcare and get the most out the medications they ...

Dr. Paul G. Donohue: Can cholesterol become too low?

Dear Dr. Donohue: I am a 78-year-old male and have blood tests and physicals every year. In 2001, my cholesterol was 225 mg/dL (5.8 mmol/L). Every year it was lower, until this year it was 94 (2.4). My LDL was 29 (.75), and my triglycerides 36 (0.4). My weight stays between 138 and 144 pounds. I am 5 feet 6 inches tall. My appetite is good. I am not nor have I ever been on a low-cholesterol diet ...

Simplified clinical tool affects treatment decisions for heart health

( Springer ) The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups ...

Simplified heart-risk guideline may miscalculate risk for millions

( University of California - San Francisco ) A method that is widely used to predict the risk of a major coronary event may over- or underestimate risk for millions of Americans, according to a study directed by a researcher at the San Francisco VA Medical Center and the University of California, San Francisco.

NIH Awards $13.23 Million to Children's Hospital Oakland Research Institute Scientist and Team

The National Institute of Health (NIH) Pharmacogenetics Research Network (PGRN) just awarded $13.23 million to Children's Hospital Oakland Research Institute (CHORI) Senior Scientist Ronald Krauss, MD, for a five-year renewal of his grant, Pharmacogenomics and Risk of Cardiovascular Disease (PARC). Dr. Krauss and the national, interdisciplinary PARC team will use the grant to continue research ...